StivargaActive Ingredient(s): Regorafenib
FDA Approved: * September 27, 2012
Pharm Company: * BAYER HEALTHCARE PHARMS
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers. Contents 1 Approvals and indications... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.
How did this drug, with its horrible side effects and minimal efficacy (6 weeks survival vs placebo), ever get approved?...1 REPLY
My father is treated for a metastatic colorectal cancer since two years and now he is resistant to all therapeutic, his ...